Press release
Persistent Corneal Epithelial Defects Treatment Pipeline Shows Strong Momentum as 5+ Pharma Companies in the Race | DelveInsight
Discover the latest drugs and treatment options in the Persistent Corneal Epithelial Defects Pipeline. Dive into DelveInsight's comprehensive report today! @ https://www.delveinsight.com/sample-request/persistent-corneal-epithelial-defects-pceds-pipeline-insight [https://www.delveinsight.com/sample-request/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Persistent Corneal Epithelial Defects Pipeline Report
* DelveInsight's Persistent Corneal Epithelial Defects pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Persistent Corneal Epithelial Defects treatment.
* The leading Persistent Corneal Epithelial Defects Companies such as Eyevance/Amber Ophthalmics, Kala Pharmaceuticals, Noveome Biotherapeutics, Oyster Point Pharma and others.
* Promising Persistent Corneal Epithelial Defects Pipeline Therapies such as ST266, KIO-201, Lufepirsen high dose and others.
Stay ahead with the most recent pipeline outlook for Persistent Corneal Epithelial Defects. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Persistent Corneal Epithelial Defects Treatment Drugs [https://www.delveinsight.com/sample-request/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Persistent Corneal Epithelial Defects Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Persistent Corneal Epithelial Defects Pipeline Report also highlights the unmet needs with respect to Persistent Corneal Epithelial Defects.
Persistent Corneal Epithelial Defects Overview
The cornea is the transparent, outermost layer of the eye that uniformly refracts the majority of light that enters the eye onto the lens and is essential for ideal vision. The multi-layered corneal epithelium acts as a protective barrier to infectious agents via tight junctions between neighboring cells, and it maintains its smooth optical surface by constantly regenerating cells in the basal cell layer. Persistent Corneal Epithelial Defects (PCEDs) (PEDs or PCEDs) result from the failure of rapid re-epithelialization and closure within 10-14 days after a corneal injury, even with standard supportive treatment. Disruptions in the protective epithelial and stromal layers of the cornea can render the eye susceptible to infection, stromal ulceration, perforation, scarring, and significant vision loss.
Persistent Corneal Epithelial Defects Emerging Drugs Profile
* KPI-012: Kala Pharmaceuticals
Kala's development pipeline includes KPI-012, in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. Kala is also evaluating KPI-012 for potential expansion to additional indications for rare front of the eye diseases, such as partial limbal stem cell deficiency and moderate-to-severe Sjogren's. KPI-012 is currently under investigation for PCED in Phase II trial which is expected to be completed in February 2024.
* Nexagon: Eyevance/Amber Ophthalmics
NEXAGON, is a first in class unmodified antisense oligodeoxynucleotide that inhibits a cell membrane hemichannel forming protein, connexin43 (Cx43). Cx43 is overexpressed after acute injury or in chronic disease states leading to pathological prematurely open hemichannels, allowing ATP to enter the extracellular space. Extracellular ATP triggers and perpetuates the immune system's inflammasome pathway releasing multiple proinflammatory cytokines resulting in microvascular breakdown, vessel leak and limbal tissue ischemia. NEXAGON inhibits Cx43 overexpression and the inflammatory cascade, re-establishing limbal microvasculature and promoting regeneration of the corneal epithelium. Amber Ophthalmics, of San Diego, which is currently developing Nexagon reported that it saw positive topline results in a Phase II trial of Nexagon (lufepirsen ophthalmic gel) for persistent corneal epithelial defect (PCED) secondary to chemical and/or thermal injury. Nexagon has been granted orphan drug status by the US FDA. Amber said it plans to begin a Phase II/III trial in subjects with PCED of various etiologies in Q1-2023.
Explore groundbreaking therapies and clinical trials in the Persistent Corneal Epithelial Defects Pipeline. Access DelveInsight's detailed report now! @ New Persistent Corneal Epithelial Defects Drugs [https://www.delveinsight.com/sample-request/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Persistent Corneal Epithelial Defects Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Persistent Corneal Epithelial Defects with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Persistent Corneal Epithelial Defects Treatment.
* Persistent Corneal Epithelial Defects Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Persistent Corneal Epithelial Defects Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Persistent Corneal Epithelial Defects market
Persistent Corneal Epithelial Defects Companies
Eyevance/Amber Ophthalmics, Kala Pharmaceuticals, Noveome Biotherapeutics, Oyster Point Pharma and others.
Persistent Corneal Epithelial Defects pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Persistent Corneal Epithelial Defects Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Unveil the future of Persistent Corneal Epithelial Defects Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Persistent Corneal Epithelial Defects Market Drivers and Barriers [https://www.delveinsight.com/sample-request/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Persistent Corneal Epithelial Defects Pipeline Report
* Coverage- Global
* Persistent Corneal Epithelial Defects Companies- Eyevance/Amber Ophthalmics, Kala Pharmaceuticals, Noveome Biotherapeutics, Oyster Point Pharma and others.
* Persistent Corneal Epithelial Defects Pipeline Therapies- ST266, KIO-201, Lufepirsen high dose and others.
* Persistent Corneal Epithelial Defects Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Persistent Corneal Epithelial Defects Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Persistent Corneal Epithelial Defects Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Persistent Corneal Epithelial Defects Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Persistent corneal epithelial defects (PCEDs): Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Persistent corneal epithelial defects (PCEDs)- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Mid Stage Products (Phase II)
* KPI-012: Kala Pharmaceuticals
* Early Stage Products (Phase I)
* Preclinical and Discovery Stage Products
* OC-01: Oyster Point Pharma
* Inactive Products
* Persistent corneal epithelial defects (PCEDs) Key Companies
* Persistent corneal epithelial defects (PCEDs) Key Products
* Persistent corneal epithelial defects (PCEDs)- Unmet Needs
* Persistent corneal epithelial defects (PCEDs)- Market Drivers and Barriers
* Persistent corneal epithelial defects (PCEDs)- Future Perspectives and Conclusion
* Persistent corneal epithelial defects (PCEDs) Analyst Views
* Persistent corneal epithelial defects (PCEDs) Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=persistent-corneal-epithelial-defects-treatment-pipeline-shows-strong-momentum-as-5-pharma-companies-in-the-race-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/persistent-corneal-epithelial-defects-pceds-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Persistent Corneal Epithelial Defects Treatment Pipeline Shows Strong Momentum as 5+ Pharma Companies in the Race | DelveInsight here
News-ID: 4360635 • Views: …
More Releases from ABNewswire
Shaun Savvy Helps Tuckaway Farm in Bentonville, Arkansas Sell Out Two CSA Season …
Buffalo-based SEO consultant Shaun Savvy partnered with Tuckaway Farm in Bentonville, Arkansas to help the farm sell out two consecutive CSA seasons, generating over $80,000 in revenue while spending less than $1,000 on paid advertising through a strategic blend of local SEO, high-intent content, and targeted social media campaigns.
Shaun Savvy, a Buffalo-based SEO and digital marketing consultant, announced a successful local marketing case study showcasing how Tuckaway Farm sold out…
Desert-Proven Skincare: How Corrective Skin LLC's Three-Decade Formula Testing C …
Corrective Skin LLC leverages the extreme conditions of the Utah desert as a rigorous testing environment for their professional-grade skincare line. With 30 years of formulation refinement in one of the country's harshest climates, the female-founded company offers growth factor treatments and advanced skincare that deliver results where other products fail.
The Utah desert presents one of the most demanding environments for skin health in North America, making it an ideal…
From College Basketball Courts to Dog Parks: Athlete Develops Weighted Training …
A former college basketball player who relied on weighted vest training for peak athletic performance has channeled that expertise into Canine Weight Set, a specialized fitness system for dogs. The innovative product line applies proven human sports training principles to canine exercise, offering dog owners a safe method to enhance their pets' strength, endurance, and overall health.
The inspiration for breakthrough products often comes from unexpected moments when personal experience intersects…
Greyhound.com - A Simple Way to Travel Across Cities
Image: https://www.abnewswire.com/upload/2026/01/22a49e0d337c211e573359c68ddad4bc.jpg
When it comes to affordable and convenient intercity travel, Greyhound.com [https://www.awin1.com/cread.php?awinmid=40028&awinaffid=1936741&clickref=182&clickref2=https%3A%2F%2Fapnews.com%2F] has become a go-to platform for many travellers. The website serves as the official online portal for Greyhound, one of the most recognized long-distance bus service providers in North America. Designed with user convenience in mind, the platform allows people to plan trips, book tickets, and manage their journeys without unnecessary complications.
One of the strongest advantages of Greyhound.com…
More Releases for Persistent
Evolving Market Trends In The Advanced Persistent Threat Protection Industry: In …
The Advanced Persistent Threat Protection Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Advanced Persistent Threat Protection Market Size During the Forecast Period?
The market size for advanced persistent threat protection has seen a substantial increase in the recent past. It is…
Advanced Persistent Threat Protection Market Size and Forecast
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Advanced Persistent Threat Protection Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
The Advanced Persistent Threat (APT) Protection market is experiencing significant growth due to the increasing frequency and sophistication of cyberattacks. APTs are long-term,…
Decentralized Identity Systems Market Dynamics and Demand A Deep Dive into Trend …
The Decentralized Identity Systems Market is an emerging and transformative sector within the blockchain and digital identity industries, offering a secure and user-centric approach to managing identity information. Decentralized identity systems empower individuals to have more control over their personal data and digital identities, reducing reliance on centralized entities for identity verification. These systems utilize blockchain technology and cryptography to provide secure, privacy-enhancing, and interoperable solutions for identity management. As…
Global Advanced Persistent Threat Protection Market
The data examined by GME predicted that by 2026, the Global Advanced Persistent Threat Protection Market would grow with a CAGR value of 19.5 percent. External threats are constantly on the lookout for opportunities to hack security networks and obtain access to sensitive data. Hence, with the rising cases of cyber security thefts or crime will help propel the market from 2021 to 2026. Moreover the market is projected to…
Pyrometer Market Expansion to be Persistent During 2028
Pyrometer Market – Notable Developments
In April 2019, AMETEK Land revealed its enhanced SPOT infrared pyrometer software packages, SPOTPro and SPOTViewer. The newly launched pyrometer packages are aimed at giving users a better understand of the performance of various processes and aid them in realizing industry 4.0 connectivity.
In December 2018, Extech announced launch of a ruggedized, dual-laser infrared (IR) thermometer named IR320, which is designed to perform rough and tough jobs…
DevSecOps Market Expansion to be Persistent during 2023
Overview:
In the recent times, a new trend is gaining popularity in the software development life cycle called DevSecOps. This technology bridges the gap between development, operations, and security teams to speed up the software development process through collaboration and communication among the teams. The goal of DevOps is to give more ownership to the development team for developing and monitoring applications. Security plays a key role by providing high-end security…
